Hallal-Longo et al. found that MS patients undergoing IFN-β therapy had increased intracellular CTLA-4 levels in PBMCs, which correlated with reduced proliferation in response to MBP and myelin, and higher lymphocyte apoptosis [35]. The gene discussed is IFNB1; the disease is myeloid sarcoma.